Oxford-AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign

被引：10

作者：

Vallee, A. ^{[1
]}

Chan-Hew-Wai, A. ^{[2
]}

Bonan, B. ^{[2
]}

Lesprit, P. ^{[3
]}

Parquin, F. ^{[4
]}

Catherinot, E. ^{[5
]}

Choucair, J. ^{[5
]}

Billard, D. ^{[6
]}

Amiel-Taieb, C. ^{[7
]}

Camps, E. ^{[2
]}

Cerf, C. ^{[8
]}

Zucman, D. ^{[9
]}

Fourn, E. ^{[9
]}

机构：

[1] Foch Hosp, Dept Clin Res & Innovat, Suresnes, France

[2] Foch Hosp, Hosp Pharm, Suresnes, France

[3] Foch Hosp, Dept Hyg & Infect Dis, Suresnes, France

[4] Foch Hosp, Intens Resp Care Dept, Suresnes, France

[5] Foch Hosp, Dept Pneumol, Suresnes, France

[6] Foch Hosp, Dept Oncol, Suresnes, France

[7] Foch Hosp, Dept Occupat Hlth, Suresnes, France

[8] Foch Hosp, Dept Intens Care, Suresnes, France

[9] Foch Hosp, Dept Internal Med, Reseau Ville Hop Val Seine, Suresnes, France

来源：

PUBLIC HEALTH | 2021年 / 196卷

关键词：

COVID-19; vaccine; AstraZeneca vaccine; Adverse effects; Vaccine campaign;

D O I：

10.1016/j.puhe.2021.05.030

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Objectives: A strong COVID-19 vaccine campaign is needed to reach the herd immunity and reduce this pandemic infection. Study design: In the Foch Hospital, France, in February 2021, 451 healthcare workers were vaccinated by a first dose of AstraZeneca vaccine. Methods: Adverse effects were reported to our pharmaco-vigilance circuit, by an online and anonymous questionnaire following the first weeks of the vaccinal campaign to healthcare workers. Results: Two hundred seventy-four (60.8%) of them reported multiple adverse effects. Main adverse effects reported were feverish state/chills (65.7%), fatigue/physical discomfort (62.4%), arthralgia/muscle pain (61.0%) and fever (44.5%). Conclusions: On March 2021 many European countries suspended AstraZeneca vaccine for one week due to safety uncertainty. Thus, confidence in its efficacy is undermined. However, the benefit/risk balance is clearly in favor of vaccination. (C) 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

引用

页码：135 / 137

页数：3

共 10 条

[1] Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination [J].

Anderson, Roy M. ;

Vegvari, Carolin ;

Truscott, James ;

Collyer, Benjamin S. .

LANCET, 2020, 396 (10263) :1614-1616

[2] Epidemiology and risk factors for venous thrombosis [J].

Cushman, Mary .

SEMINARS IN HEMATOLOGY, 2007, 44 (02) :62-69

[3] Interrupting vaccination policies can greatly spread SARS-CoV-2 and enhance mortality from COVID-19 disease: The AstraZeneca case for France and Italy [J].

Faranda, Davide ;

Alberti, Tommaso ;

Arutkin, Maxence ;

Lembo, Valerio ;

Lucarini, Valerio .

CHAOS, 2021, 31 (04) :1ENG

[4] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial [J].

Folegatti, Pedro M. ;

Ewer, Katie J. ;

Aley, Parvinder K. ;

Angus, Brian ;

Becker, Stephan ;

Belij-Rammerstorfer, Sandra ;

Bellamy, Duncan ;

Bibi, Sagida ;

Bittaye, Mustapha ;

Clutterbuck, Elizabeth A. ;

Dold, Christina ;

Faust, Saul N. ;

Finn, Adam ;

Flaxman, Amy L. ;

Hallis, Bassam ;

Heath, Paul ;

Jenkin, Daniel ;

Lazarus, Rajeka ;

Makinson, Rebecca ;

Minassian, Angela M. ;

Pollock, Katrina M. ;

Ramasamy, Maheshi ;

Robinson, Hannah ;

Snape, Matthew ;

Tarrant, Richard ;

Voysey, Merryn ;

Green, Catherine ;

Douglas, Alexander D. ;

Hill, Adrian V. S. ;

Lambe, Teresa ;

Gilbert, Sarah C. ;

Pollard, Andrew J. .

LANCET, 2020, 396 (10249) :467-478

[5] COVID-19 herd immunity: where are we? [J].

Fontanet, Arnaud ;

Cauchemez, Simon .

NATURE REVIEWS IMMUNOLOGY, 2020, 20 (10) :583-584

[6] VIEWPOINT: COVID-19 Understanding COVID-19 vaccine efficacy [J].

Lipsitch, Marc ;

Dean, Natalie E. .

SCIENCE, 2020, 370 (6518) :763-765

[7] Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency [J].

Mahase, Elisabeth .

BMJ-BRITISH MEDICAL JOURNAL, 2021, 372

[8]

PINHO AC, 2021, COVID 19 VACCINE AST COVID 19 VACCINE AST

[9] COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics [J].

Schwarzinger, Michael ;

Watson, Verity ;

Arwidson, Pierre ;

Alla, Francois ;

Luchini, Stephane .

LANCET PUBLIC HEALTH, 2021, 6 (04) :E210-E221

[10] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials [J].

Voysey, Merryn ;

Clemens, Sue Ann Costa ;

Madhi, Shabir A. ;

Weckx, Lily Y. ;

Folegatti, Pedro M. ;

Aley, Parvinder K. ;

Angus, Brian ;

Baillie, Vicky L. ;

Barnabas, Shaun L. ;

Bhorat, Qasim E. ;

Bibi, Sagida ;

Briner, Carmen ;

Cicconi, Paola ;

Clutterbuck, Elizabeth A. ;

Collins, Andrea M. ;

Cutland, Clare L. ;

Darton, Thomas C. ;

Dheda, Keertan ;

Dold, Christina ;

Duncan, Christopher J. A. ;

Emary, Katherine R. W. ;

Ewer, Katie J. ;

Flaxman, Amy ;

Fairlie, Lee ;

Faust, Saul N. ;

Feng, Shuo ;

Ferreira, Daniela M. ;

Finn, Adam ;

Galiza, Eva ;

Goodman, Anna L. ;

Green, Catherine M. ;

Green, Christopher A. ;

Greenland, Melanie ;

Hill, Catherine ;

Hill, Helen C. ;

Hirsch, Ian ;

Izu, Alane ;

Jenkin, Daniel ;

Joe, Carina C. D. ;

Kerridge, Simon ;

Koen, Anthonet ;

Kwatra, Gaurav ;

Lazarus, Rajeka ;

Libri, Vincenzo ;

Lillie, Patrick J. ;

Marchevsky, Natalie G. ;

Marshall, Richard P. ;

Mendes, Ana V. A. ;

Milan, Eveline P. ;

Minassian, Angela M. .

LANCET, 2021, 397 (10277) :881-891

← 1 →